LimmaTech Appoints Staph Leavenworth Bakali as Chairman of the Board
July 01 2024 - 5:00AM
Business Wire
LimmaTech Biologics AG, a clinical-stage biotech company
developing vaccines for the prevention of life-threatening
diseases, today announced the appointment of Staph Leavenworth
Bakali as independent Chairman of its Board of Directors. Mr.
Leavenworth Bakali brings over 30 years of senior executive and
board-level experience in the life science and healthcare
industries. He has led early-stage and mature companies through
product development, growth, and commercialization while raising
significant capital and has been closely involved in several
successful exits. He succeeds Dr. Philippe Dro, who will remain a
member of the Board of Directors representing Adjuvant Capital.
"Staph is an exceptional leader, knowing what it takes to
transform vaccine candidates into commercial products, and we will
greatly benefit from his deep global experience as we advance our
pipeline towards the next key milestones," said Dr. Franz-Werner
Haas, CEO of LimmaTech. "His background in commercial and
impact-driven enterprises, familiarity with high and low to
middle-income countries, and roles in large and small companies
brings valuable expertise to LimmaTech's mission to address the
global threat of antimicrobial resistance while generating value
for our stakeholders. I would like to thank Philippe for his
dedication and guidance as Chair since the genesis of LimmaTech and
am delighted that he will continue contributing to LimmaTech on the
Board."
Staph Leavenworth Bakali added, "As antimicrobial
resistance continues to rise globally, infections will become
increasingly difficult or impossible to treat. LimmaTech is at the
forefront of combating this epidemic with a robust pipeline of
vaccine candidates that can mitigate this escalating risk and
control several highly transmissible pathogens. I look forward to
sharing my experience and working with the LimmaTech team in our
mission to address significant global medical needs and making a
meaningful impact on people’s lives."
Mr. Leavenworth Bakali most recently served as Chief Executive
Officer (CEO) and President of George Health Enterprises, the
commercial arm of The George Institute for Global Health, a leading
medical research institute. In this role, he was deeply involved in
establishing and growing a portfolio of companies focused on
providing market-disruptive treatments, technologies, devices, and
services addressing the large and fast-growing global chronic
disease market. Previously, he served as President and Chief
Operating Officer at the Clinton Health Access Initiative (CHAI), a
non-profit organization founded by former U.S. President Bill
Clinton. Mr. Leavenworth Bakali held several senior leadership
roles in the vaccine industry, including CEO and Director of
vaccine development companies Genocea Biosciences and Intercell,
respectively. He served as Chief Operating Officer at ID Biomedical
and PowderJect Pharmaceuticals, which were acquired by
GlaxoSmithKline and Chiron, respectively. He served as the Global
Commercial Head of Sales for Chiron’s global vaccine business and
the Director of SmithKline Beecham’s vaccine business unit in
France. Mr. Leavenworth Bakali holds a Masters in Management from
the London Business School.
About LimmaTech Biologics
LimmaTech Biologics is at the forefront of combating the global
antimicrobial resistance epidemic based on its unparalleled track
record in vaccine technology and clinical candidate development.
The company is leveraging its proprietary self-adjuvanting and
multi-antigen vaccine platform alongside additional
disease-specific vaccine approaches to prevent increasingly
untreatable microbial infections. With decades of expertise and an
expanding, robust pipeline, the LimmaTech team is dedicated to
generating protective solutions to deliver transformative value
worldwide.
LimmaTech Biologics is backed by specialist healthcare
investors, including Adjuvant Capital, AXA IM Alts, Novo Holdings
REPAIR Impact Fund, and Tenmile.
For more information, please visit www.lmtbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240701325287/en/
LimmaTech Biologics AG Franz-Werner Haas, CEO E-Mail:
media@lmtbio.com
For media enquiries Sara Ortiz or Jacob Verghese Trophic
Communications Phone: +49 151 7441 6179 Email:
limmatech@trophic.eu